In a historic move, U.S. public health agencies announced a sweeping effort to investigate the causes of autism, pledging to examine every possible factor — including vaccines, pharmaceuticals, and environmental exposures. The announcement came during a White House event featuring Health Secretary Robert F. Kennedy Jr., President Donald Trump, and other officials, signaling the most comprehensive federal inquiry into autism ever undertaken.
Kennedy emphasized that the government would pursue answers with “uncompromising and relentless” determination. He noted that for decades, scientific and regulatory bodies largely focused on genetic explanations for autism while ignoring widespread parental concerns about environmental triggers. He stated that “70% of mothers who have children with autism believe their child was injured by a vaccine,” adding that these voices would no longer be marginalized.
President Trump echoed those concerns, arguing that vaccines and the modern childhood immunization schedule may be contributing to the surge in autism and chronic illness. “Since 2000, autism rates have surged by much more than 400%,” Trump said, citing CDC data that shows 1 in 31 children had an autism diagnosis in 2022, compared with 1 in 36 in 2020 and 1 in 1,000 in the 1990s. He described current vaccine practices as excessive, saying, “They pump so much stuff into those beautiful little babies … it’s a disgrace.”
Alongside the autism research initiative, the Food and Drug Administration (FDA) announced immediate action on two fronts. First, new warning labels will be added to acetaminophen products, including Tylenol, alerting pregnant women to a possible link between prenatal use and autism. This decision follows multiple studies, including research from Harvard and Mount Sinai, suggesting biological mechanisms by which acetaminophen exposure could alter brain development. Shares of Kenvue Inc., the maker of Tylenol, dropped nearly 7.5% on the news. Second, the FDA signaled approval of leucovorin — a drug traditionally used in cancer care — as a treatment for autism-related symptoms, particularly in children with folate deficiencies.
Reactions from the autism community were swift. Mary Holland, CEO of Children’s Health Defense, called the announcement “historic,” marking the first time federal officials have acknowledged both environmental contributors to autism and treatment pathways for affected children. John Gilmore of the Autism Action Network said the initiative “shattered two taboos”: that autism may be environmentally driven and that medical advice, such as recommending Tylenol to pregnant women, could have contributed to the condition.
The initiative includes the launch of the Autism Data Science Initiative, coordinated by the National Institutes of Health (NIH), involving 13 federally funded research teams. More than 100 proposals have been submitted for study participation. The scope is wide, examining not only vaccines and pharmaceuticals but also food additives, water and air pollutants, and other environmental exposures.
Kennedy reminded the public that in 1978 autism affected fewer than 1 in 10,000 children, underscoring the scale of the modern epidemic. Trump concluded by expressing optimism, stating that if the causes can be identified and addressed, “that’s going to be a great thing.”
This unprecedented federal effort marks a turning point in autism research, with a new commitment to transparency, environmental inquiry, and potential medical interventions.
Bookmark Vaccines.news to your favorite independent websites for updates on experimental gene therapy injections (mRNA) that lead cause autism, along with the MMR and the multi-dose mercury-laced flu shots.
Sources for this article include: